Role of vesicular monoamine transporter-2 for treating attention deficit hyperactivity disorder: a review.
Saved in:
| Title: | Role of vesicular monoamine transporter-2 for treating attention deficit hyperactivity disorder: a review. |
|---|---|
| Authors: | Warlick IV, Halford (AUTHOR), Tocci, Darcy (AUTHOR), Prashar, Sukriti (AUTHOR), Boldt, Erick (AUTHOR), Khalil, Alena (AUTHOR), Arora, Simran (AUTHOR), Matthews, Thomas (AUTHOR), Wahid, Talha (AUTHOR), Fernandez, Richard (AUTHOR), Ram, Dhiya (AUTHOR), Leon, Lexie (AUTHOR), Arain, Arisha (AUTHOR), Rey, Jose (AUTHOR), Davis, Kelley (AUTHOR) |
| Source: | Psychopharmacology. Nov2024, Vol. 241 Issue 11, p2191-2203. 13p. |
| Subjects: | Attention-deficit hyperactivity disorder, Omega-3 fatty acids, Monoamine transporters, Dietary supplements |
| Abstract: | Rationale: The Diagnostic and Statistical Manual of Mental Disorders (Fifth Edition) classifies attention deficit hyperactivity disorder (ADHD) as a neurodevelopmental disorder that interferes with human functioning and development. As the clinical presentation of ADHD involves a deficiency in executive function, neurocognitive deficits involving distinctive neuropathological changes must be present for clinical diagnosis. Objectives: The vesicular monoamine transporter (VMAT), specifically VMAT-2, plays a role in ADHD pathogenesis. In addition, experimental data show that the stimulants (amphetamines and methylphenidate) are first-line treatments for the condition because of their extensive interaction with VMAT-2. The interactions of peptides, bupropion, and nutritional supplements with VMAT-2 receptors have been researched, but more evidence is needed to elucidate their pharmacodynamic properties. Therefore, this literature review evaluated the current pharmacological treatment modalities, peptides, and nutritional supplements for ADHD that target the VMAT-2 system. Methods, results, and conclusions: We obtained relevant studies from several platforms, including the National Center for Biotechnology, Clinical Key, Access Medicine, and PubMed. From the results of these studies, we observed that stimulants interact highly with the VMAT-2 transporter, with omega-3 fatty acids, peptides, and bupropion exerting some modulatory activity on VMAT-2. These agents should be considered for the future treatment of ADHD, although clinical-level research involving human participants is necessary. [ABSTRACT FROM AUTHOR] |
| Copyright of Psychopharmacology is the property of Springer Nature and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) | |
| Database: | Psychology and Behavioral Sciences Collection |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
